Key takeaway: Aether Industries Limited's investor presentation for Q2 and H1 FY27 highlights strong financial performance driven by its Contract and Exclusive Manufacturing (CEM) and Contract Research & Manufacturing Services (CRAMS) business models, which contributed 66% of revenue and are projected to reach 70% in the next two years. Revenue for H1 FY27 reached ₹6,738 million, reflecting a 27% year-over-year increase, with EBITDA at ₹2,132 million (+30% Y/Y) and Profit After Tax (PAT) at ₹1,307 million (+29% Y/Y). Key operational developments include the commencement of commercial production at Site 3++, Phase One of Site 5 with two production blocks operational since Q1 FY27, and 18 new fume hoods installed in R&D facilities. The company also onboarded six new customers across all business models and is expanding its R&D center. By segment, Oil and Gas and Material Science remain the primary revenue drivers, despite new product launches in Pharmaceuticals and Agrochemicals. The consolidated financial results show robust operating income and margin growth, supported by a shift in segment mix and strong customer traction across sectors. The standalone financial results also reflect similar growth trends, with H1 FY27 revenue at ₹5,310 million and PAT at ₹1,002 million. The company reported significant investments in R&D, with ₹406.01 million spent in HFY27, accounting for 6.03% of revenue. Capital expenditures and R&D expansion are ongoing, with new facilities under construction and planned for completion by Q1 FY28. The consolidated balance sheet shows strong asset base and liquidity, with total assets at ₹36,023 million as of H1 FY27. The cash flow statement indicates net cash generated from operations and financing activities, supporting the company's growth initiatives and operational expansion.

Key takeaway: Aether Industries Limited reported a strong quarterly performance with a 27% year-on-year sales growth and a 7% quarter-on-quarter increase. Management noted that all three business verticals are performing well, with Contract and Exclusive Manufacturing (CEM) growing approximately 75% year-on-year and Contract Research and Manufacturing Services (CRAMS) growing about 20% year-on-year. CRAMS and CEM now contribute 60% of total revenue, with a goal to reach 70% in the coming years. The company completed the installation of additional equipment at its R&D center and reported stable raw material procurement. Capital expenditure for the quarter was approximately !1,000 million for the new R&D center and !833 million for Site Magnum. EBITDA margin improved to 31.47% from 30.61% year-on-year, reflecting increased contributions from CRAMS and CEM. As of June 30, 2026, total borrowings were !5,215 million.

Key takeaway: Aether Industries Limited reported its financial results for the first quarter ended June 30, 2026, highlighting a year-over-year revenue increase of 27% to INR 3,342 million. The company noted that Contract Research and Manufacturing Services (CRAMS) and Contract Exclusive Manufacturing (CEM) contributed 60% of revenue, with a goal to reach 70% in the next two years. The presentation indicated that commercial production at SITE 3 had commenced, and Phase One of SITE 5 began operations in Q1 FY27. Aether onboarded 10 new customers and completed 9 customer and certification audits during the quarter. The company spent INR 198.07 million on R&D, accounting for 6.16% of revenues. Profit After Tax increased by 33% year-over-year to INR 627 million, attributed to improved profitability and a favorable shift in segment mix. The document provided detailed financial results, including EBITDA and segment contributions.

Key takeaway: Aether Industries Limited held its Q4 and FY26 Earnings Conference Call on May 15, 2026, where management discussed the company's financial performance and strategic initiatives. Management reported a 38% year-on-year increase in consolidated revenue for FY26, reaching INR 11,601 million, with a 53% rise in EBITDA. The company highlighted strong pricing in its large-scale manufacturing segment, with prices up 20% year-on-year. Management noted the commissioning of new products in pharmaceuticals and agrochemicals, contributing to sales growth. R&D expansions were also emphasized, with new labs and equipment aimed at enhancing capabilities. The company aims for 70% of revenues to come from CRAMS and CEM by FY30. Despite challenges from recent global disruptions, management expressed confidence in sustained demand and pricing stability. The call concluded with a focus on operational execution and strategic growth initiatives.

Key takeaway: Aether Industries Limited reported strong financial performance for the fourth quarter and fiscal year ended March 31, 2026, with revenue increasing by 38% year-over-year to ₹11,601 million, EBITDA rising by 53% to ₹3,547 million, and profit after tax (PAT) growing by 39% to ₹2,195 million. The company highlighted that its Contract Exclusive Manufacturing (CEM) and Contract Research and Manufacturing Services (CRAMs) business models contributed over 55% of total revenue. The presentation noted the commencement of production at Site 3++ in February 2026 and the onboarding of 19 new customers during the fiscal year. Additionally, Aether reported an increase in R&D expenditure, which accounted for 7.3% of revenues, and outlined ongoing expansions in its R&D facilities. The document emphasized operational excellence, with 50 customer and certification audits accomplished in FY26.

Key takeaway: Aether Industries Limited held its Q3 FY '26 Earnings Conference Call on February 3, 2026, to discuss its financial performance for the third quarter and nine months ended December 31, 2025. Management reported that the construction and installation of Site 3++ and the first two production blocks of Site 5 were completed, with commercial production commencing shortly. The company achieved a consolidated revenue of INR 3,171 million for Q3 FY '26, marking a 44% year-on-year increase. EBITDA rose to INR 1,083 million, a 75% increase compared to the previous year. Management highlighted strong demand in large-scale manufacturing, with a volume growth of over 10% quarter-on-quarter. The company also added new products and clients, particularly in the pharmaceutical and agrochemical sectors. R&D expansions were noted, focusing on non-pharma and non-agro sectors. The management expressed optimism about future growth despite a volatile global environment.